



# ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: [www.americasblood.org](http://www.americasblood.org)

2024 #31

September 13, 2024

## INSIDE:

- CMS Approves New HCPCS Code: RBCs, Leukocytes Reduced, Oxygen/Carbon Dioxide Reduced, Each Unit .....2
- WORD IN WASHINGTON .....2
- BRIEFLY NOTED.....3
- ABC WELC Webinar Set for September 26<sup>th</sup>.....4
- ABC Talking Points on Importance of Community Blood Centers.....4
- ABC Announces Cybersecurity Webinar on September 17<sup>th</sup> .....4
- Last Call: Register for the 2024 ADRP Master Class .....4
- Register for ABC WELC Rise & Lead Workshop.5
- MEMBER NEWS.....5
- GLOBAL NEWS .....6
- COMPANY NEWS .....7
- CALENDAR.....8
- POSITIONS.....9

## New ABC Executive Fellows Program

America's Blood Centers (ABC) in partnership with Vanderbilt University's Owen School of Management has launched the [Executive Fellows Program \(EFP\)](#). This groundbreaking new initiative offers industry-specific, best-in-class leadership training to blood community executives, elevating individuals, organizations, and the nation's blood supply.



The program will accept an annual cohort of up to 25 fellows, with the first cohort starting in March 2025. A call for applications will occur at the beginning of October with final selections for the first cohort by December 2024. Senior leaders from ABC member blood centers, hospital-associate members, affiliate organizations, and industry partners are encouraged to apply.



**VANDERBILT**  
Owen Graduate School  
of Management

Through the EFP, individuals will be uniquely equipped with the business acumen and executive skill set needed to succeed in the blood community's quickly and ever-evolving environment. The EFP also features a week-long Leadership Residency at Vanderbilt each fall, three additional in-person learning immersions throughout the year, virtual seminars taught by Vanderbilt faculty, a 360-leadership assessment, individual executive coaching, a capstone project, and more.

A limited number of partial scholarships will be made available to eligible blood center employees each year through the Foundation for America's Blood Centers (FABC).

Additional information on the EFP can be found on the program's [website](#). A [slide deck](#) with more details is also available to ABC members on [CollABORate](#). 💧



**Elevate your leadership journey!**  
Join us in San Antonio, TX  
November 6th & 7th

[Register Now](#)

A WOMEN'S LEADERSHIP WORKSHOP



## CMS Approves New HCPCS Code: RBCs, Leukocytes Reduced, Oxygen/Carbon Dioxide Reduced, Each Unit

The Centers for Medicare & Medicaid Services (CMS) has [approved](#) a new Healthcare Common Procedure Coding System (HCPCS) code for “red blood cells (RBCs), leukocytes reduced, oxygen/ carbon dioxide reduced, each unit,” according to a news release from Hemanext. The new code is P9027 for RBCs, leukocytes reduced, oxygen/carbon dioxide reduced, each unit” manufactured with Hemanext ONE by Hemanext, Inc.

America’s Blood Centers and the blood community previously submitted [comments](#) in July 2024 to CMS, in [response](#) to the agency’s [HCPCS Level II Code Public Meeting](#) from May 2024, that urged the agency to, “revisit and approve” the submitted application for establishment of a new HCPCS Level II that, “identifies RBCs, Leukocytes Reduced, Oxygen/Carbon Dioxide Reduced.” The organizations commended CMS in the Hemanext news release, “for supporting patients access to novel products [by approving the new [HCPCS code].”

According to Hemanext, “red blood cells, leukocytes reduced, oxygen/carbon dioxide reduced are also known as hypoxic red blood cells (HRBCs). The Hemanext ONE RBC Processing and Storage System (Hemanext, Inc.) that produces HRBCs, was developed to limit the detrimental effects of oxidative damage on RBCs during storage, and designed to bring new levels of innovation, clinical value and consistency to transfusion medicine...The new HCPCS code facilitates streamlined billing and coding processes, ensuring that healthcare providers can efficiently incorporate HRBCs into their patient care protocols. This update is expected to support better integration of HRBCs into routine clinical practice and enhance accessibility of this novel innovation for patients and healthcare providers.”

(Source: Hemanext Inc. [News Release](#), 9/9/24) ◆

## WORD IN WASHINGTON

**The Centers for Disease Control and Prevention (CDC) has published a [notice](#) in the *Federal Register* announcing the next meeting of the Clinical Laboratory Improvement Advisory Committee (CLIAAC).** According to the announcement, the virtual meeting will focus on, “reports from two CLIAAC workgroups, the Biosafety Workgroup and the Next Generation Sequencing Workgroup; cybersecurity requirements in the clinical laboratory; the determination of clinically relevant range of values for proficiency testing samples; and the utilization of remote technology for competency assessments.” The meeting is set to take place on November 6<sup>th</sup>-7<sup>th</sup> from 11 a.m. to 5 p.m. EST.

(Source: *Federal Register* [Notice](#), 9/9/24)

**The U.S. Department of Health and Human Services (HHS), through the Office of the Assistant Secretary for Health (OASH) and the Health Resources and Services Administration (HRSA), have [proposed](#) a rule that would, “amend the regulations implementing the National Organ Transplant Act of 1984.”** Specifically, the [changes](#) in the proposed rule would, “remove clinical research and institutional review board (IRB) requirements for transplantation of kidney and livers from donors with human immunodeficiency virus (HIV) to recipients with HIV. The proposed rule, Organ Procurement and Transplantation: Implementation of the HIV Organ Policy Equity (HOPE) Act, is based on rigorous analysis of clinical data. The HOPE Act, signed into law on November 21, 2013, allows organs from donors with HIV to be transplanted into candidates with HIV, under research protocols designed to evaluate the feasibility, effectiveness, and safety of such organ transplants. Participating hospitals conduct transplants under IRB-approved research protocols conforming to the National Institutes of Health (NIH) standards titled ‘HOPE Act Safeguards and Research Criteria for Transplantation of Organs Infected with HIV.’ This proposed rule

(continued on page 3)



## WORD IN WASHINGTON (continued from page 2)

applies to HOPE Act liver and kidney transplants.” According to the agency news release, “HHS expects this rule will allow a larger number of transplant centers to conduct HOPE Act kidney and liver transplants and will help reduce the stigma and health disparities associated with HIV.” Public comments are due October 15<sup>th</sup>.

(Source: HHS [News Release](#), 9/12/24) 💧

## BRIEFLY NOTED

A review published in the *Clinical Cancer Research* found that, “CAR T-cell therapy carried a risk of second primary malignancy (SPM) that was no worse than that of other standard-of-care (SOC) cancer therapies, according to a systematic literature review and meta-analysis,” explained a *MedPage Today* [article](#). Kai Rejeski, MD, an author of the review, told the news publication that, “[c]urrently, I would not say that there is strong evidence that, relative to other treatment modalities, there is an increased risk for developing SPMs with CAR T-cell therapy. I think what that really does is question, to some extent, the black-box warning label by the U.S. Food and Drug Administration (FDA).” The [review](#) analysis, “showed a 5.8 percent rate of SPM among 5,517 patients with a median follow-up of 21.7 months. The rate did not vary according to the type of disease treated or the CAR T-cell product used. The only factors associated with a higher rate of SPM were study setting (clinical trial vs. real-world experience), longer duration of follow-up, and number of therapies prior to CAR-T treatment... The 5.8 percent overall rate of SPM did not differ significantly by T-cell product or indication for treatment. The authors found a significant association between follow-up duration and SPM (P=0.009). The SPM rate was 8.5 percent among patients followed longer than the median of 21.7 months versus 4.2 percent for those with shorter follow-up (P<0.001).” The FDA previously [announced](#) in January 2024 that it has issued “safety labeling change notification letters to all manufacturers of licensed BCMA-directed and CD19-directed genetically modified autologous CAR T cell immunotherapies requiring a revision to the package insert due to risk of T-cell malignancies, with serious outcomes, including hospitalization and death.” This change notification comes in the wake of the agency publishing a [safety communication](#) in November 2023 noting that the FDA was investigating reports of T-cell malignancy in individuals who received treatment with BCMA- or CD19-directed autologous CAR T-cell immunotherapies.

(Source: *MedPage Today*, “[Second Malignancy Risk With CAR T-Cell Therapy on Par With Other Treatments](#),” 9/11/24) 💧

The *ABC Newsletter* (ISSN #1092-0412) is published by America’s Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2024 by America’s Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher (ABC members need not obtain prior permission if proper credit is given).

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognizes the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies, and programs that increase awareness about the need for blood donation; and serve as a thought leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

### America’s Blood Centers

Chief Executive Officer: Kate Fry  
Chief Medical Officer: Jed Gorlin  
Editor: Mack Benton  
Subscriptions Manager: Leslie Maundy  
**Annual Subscription Rate: \$420**

Send subscription queries to  
[memberservices@americasblood.org](mailto:memberservices@americasblood.org)  
America’s Blood Centers  
1717 K St. NW, Suite 900, Washington, DC 20006  
Phone: (202) 393-5725  
Send news tips to [newsletter@americasblood.org](mailto:newsletter@americasblood.org).



**America's Blood Centers®**  
It's About *Life*.

## INSIDE ABC

*The programs and services described in the Inside ABC section are available to ABC member blood centers and their staffs only, unless otherwise specified.*

### **ABC WELC Webinar Set for September 26<sup>th</sup>**

The next America's Blood Centers (ABC) Women's Executive Leadership Community (WELC) Webinar: "Authentic Confidence" will take place on September 26<sup>th</sup> at 3 p.m. EDT. The featured speaker for this webinar is Brian Rollefson, founder of Live Wide Leadership and vice president of Human Resources and Organizational Infrastructure at The Community Blood Center. This interactive program will guide participants on their confidence-building journey, providing tools and insights to leverage your inherent strengths, resolve areas for development, and propel yourself to your maximum potential. Through an intuitive confidence profile assessment, participants will increase their self-awareness, leading to stronger relationships, better communication, and transformation from inner critic to future influencer. More information and link to registration are available to ABC members [here](#).

### **ABC Talking Points on Importance of Community Blood Centers**

ABC has published [talking points](#) that highlight the importance of community blood centers and their unique role in meeting the constant demand for blood transfusions. ABC members can access this document and ABC's talking points library on [CollABORate](#). These talking points can be customized and used with stakeholders.

### **ABC Announces Cybersecurity Webinar on September 17<sup>th</sup>**

The next ABC Education Committee Webinar titled "Cybersecurity: Threats & Preventative Actions" will occur on September 17<sup>th</sup> at 3 p.m. EDT. The webinar will cover the topics of threat landscape and best practices for the prevention of cyberattacks. Featured speakers include George Chacko, CISSP, HCSSP, PMP, executive director of Information Security and Compliance at New York Blood Center Enterprises and Saiyed Iqbal, CRISC, CGEIT, CNE, director of Information Services at LifeStream. More information and a link to register are available [here](#).

### **Last Call: Register for the 2024 ADRP Master Class**

Time is running out to [register](#) for the 2024 ADRP Master Class: "Bring in the Coach — The Path to Effective Leadership!" Do not miss your shot to grow and learn. This virtual event is taking place September 18<sup>th</sup>-19<sup>th</sup> and will include:

- Health Psychologist Nicole Eull;
- Leadership Coach Jonathan R. Parker;
- Leadership Expert William B. Henry; and
- Business Strategy and Development Leader Dr. Meghan Kinter.

The full schedule of speakers is [available](#) as the [2024 Master Class](#) promises an interactive journey filled

(continued on page 5)





## INSIDE ABC (continued from page 4)

with powerful insights, practical tools, and actionable strategies. Gain the skills you need to enhance communication, build effective teamwork, and boost emotional intelligence. This is your opportunity to leave the bench and master effective leadership. Secure your spot today and equip yourself with the knowledge and expertise needed to lead your team to victory. When we thrive, patients thrive. Grab your clipboard, [register today](#), and get ready to elevate your team to new heights!

### Register for ABC WELC Rise & Lead Workshop

[Registration](#) is open for the ABC Women's Executive Leadership Community's (WELC) [Rise & Lead Workshop](#). This event will take place November 6<sup>th</sup> -7<sup>th</sup> in San Antonio, Texas at the Hyatt Regency Hill Country Resort. The workshop will ignite meaningful conversations and cultivate diverse perspectives. This event goes beyond traditional conferences by encouraging dynamic conversations that spark connections and drive personal and professional growth. At the Rise & Lead Workshop, you will delve into topics that matter, participate in interactive networking sessions, and walk away with tangible, real-life strategies to become a more resilient leader in today's ever-evolving world. Elevate your leadership journey with us! The full [agenda](#) is available. [Book](#) your room by October 9<sup>th</sup> to secure the group rate. 💧

## MEMBER NEWS

**Versiti** [held](#) a groundbreaking ceremony this week for the expansion of the Versiti Blood Research Institute (VBRI). According to a blood center news release, the facility will be located at, "the Milwaukee Regional Medical Center campus in Wauwatosa. Construction on the expansion project is scheduled to begin this month with an estimated completion date in 2026." The state-of-the-art facility expansion includes a, "79,000 square-foot addition that will nearly double VBRI's research capacity, add approximately 100 new jobs, and generate an estimated \$19 million in additional tax revenue for the state of Wisconsin over 30 years. The new addition will expand the VBRI's research capacity and promote the discovery of novel, more effective and less toxic therapies for a broad range of conditions that affect millions, positively impacting the health of residents across the state, nation, and international community." Versiti President and Chief Executive Officer Chris Miskel, MBA explained in the news release, "[t]oday we celebrate a pivotal moment for the future of blood health as we break ground [on the VBRI expansion.] This new, world-class facility will open in Wisconsin during 2026. We will attract leading scientific minds and fuel groundbreaking research, turning discoveries into lifesaving treatments that transform patient care worldwide." The \$79 million expansion will include, "donations and private funding. The State Building Commission released \$10 million to support the VBRI's plans to build the addition, reaffirming the state's commitment to advancing blood health research."



*Photo courtesy of Versiti*

(Source: Versiti [News Release](#), 9/10/24)

(continued on page 6)





## MEMBER NEWS (continued from page 5)

In recognition of September 11<sup>th</sup>, **New York Blood Center** held [several](#) blood drives on Wednesday encouraging individuals to remember and honor the victims of the 9/11 attacks by giving back on the National Day of Service and Remembrance. “New Yorkers have always come together to give back to their communities and help their neighbors. We encourage folks to continue this annual day of service in loving memory of those who tragically lost their lives twenty-three years ago,” stated Andrea Cefarelli, senior vice president of New York Blood Center to the *Yonkers Times*.

(Source: *Yonkers Times*, “[New York Blood Center — honor 9/11 victims by donating blood](#)”, 9/9/24) ◆

## GLOBAL NEWS

**Roche has received [approval](#) from the European Commission (EC) for a monoclonal antibody treatment that, “has the potential to reduce treatment burden for people with paroxysmal nocturnal h[e]moglobinuria (PNH) in Europe and their caregivers.”** According to a company news release, PiaSky® (crovalimab), “inhibits the complement protein C5, for adults and adolescents (12 years of age or older with a weight of 40 kg and above) with PNH who are either new to, or have been previously treated with C5 inhibitors. PNH is a rare and life-threatening blood condition where red blood cells are destroyed by the complement system — part of the innate immune system — causing symptoms such as an[e]mia, fatigue and blood clots, and potentially leading to kidney disease.” The treatment is, “the first monthly subcutaneous (SC) treatment for PNH in the European Union (EU), with the option to self-administer following adequate training.” The approval is based on data from the, “[p]hase III COMMODORE 2 study in people with PNH who have not been previously treated with C5 inhibitors. The study demonstrated that PiaSky, administered as SC injections every four weeks, achieved disease control and was well-tolerated. PiaSky was non-inferior with comparable safety to eculizumab, an existing standard of care C5 inhibitor, given intravenously every two weeks. The rate of adverse events in people treated with PiaSky was similar to treatment with eculizumab. The application included supportive data from two additional Phase III studies, the COMMODORE 1 study, in people with PNH switching from currently approved C5 inhibitors, and the COMMODORE 3 study in people new to C5 inhibitor treatment in China.” The monoclonal antibody treatment has been previously approved for use in several countries including the U.S. and Japan.

(Source: Roche [News Release](#), 8/27/24)

**The Australian Red Cross Lifeblood will [begin](#) a trial of a new pop-up donor center this month.** The 12-month trial will take place in western Australia (WA) as the pop-up donor center will rotate across eight sites, “based on several factors including proximity to Lifeblood processing cent[ers], population size, estimated donation rate, suitable venue availability, access to regional communities, and availability of qualified staff.” According to the Lifeblood announcement, “[p]op-up donor cent[ers] are mobile donor cent[ers] that operate from a local venue, such as a community hall, and are set up and packed down for each visit.” At the conclusion of the 12-month trial, the organization plans to, “review how well appointments have been filled.” Lifeblood Director of Donor Relations Steve Eldridge explained, “[f]or the past eight months we’ve had a dedicated team working very hard to get our new pop-up cent[er] trial up and running as quickly as possible. This has involved conducting extensive research and analysis to identify suitable locations and working through operational logistics and licensing for each of the eight sites.”

(Source: Lifeblood [News Release](#), 8/26/24) ◆



## COMPANY NEWS

**Safi Biotherapeutics** [announced](#) this week that it has secured an additional \$5 million in seed funding to help with, “the development of manufactured red blood cells (mRBCs) as an alternative to donor blood transfusions. The company has previously received over \$15 million in funding from the U.S. Department of Defense (DoD) which has helped Safi, “and its government program partners to demonstrate that an mRBC transfusion product is commercially feasible, the seed financing accelerates the clinical production and regulatory path toward [an investigational new drug (IND) application submission] to the U.S. Food and Drug Administration (FDA) and initial clinical trials. It also allows Safi to expand its team of experts in cell therapy product development and bring in additional regulatory, clinical strategy, and commercialization thought leaders.” Safi anticipates that this round of funding, led by J2 Ventures, will allow the company to, “deliver on its mission to make biomanufactured blood through a true public-private partnership, catalyzing the manufacturing scale-up, non-clinical studies, and US FDA regulatory activities required to initiate clinical trials for mRBCs at a multi-unit transfusion scale.”

(Source: Safi Biotherapeutics [News Release](#), 9/11/24)

**Terumo Blood and Cell Technologies** (Terumo BCT) has [partnered](#) with **Anthony Nolan**, a stem cell charity, to supply the new Anthony Nolan Cell Collection Cent[er] in Nottingham in the United Kingdom (UK) with apheresis systems. According to a Terumo BCT News release, the company will be providing the collection center, which aims to assist patients while enabling cell and gene therapy research, with the, “Spectra Optia™ Apheresis Systems for cell collection.”

(Source: Terumo BCT [News Release](#), 9/11/24)

**Fresenius Kabi** has been [honored](#) with a 2024 Trailblazer Award for supply chain innovation from Premier Inc. According to a company announcement, the recognition is a result of, “Fresenius Kabi’s exceptional partnership and investments in U.S. manufacturing and supply chain resiliency. The Trailblazer award recognizes a Premier Inc. national contracted supplier that uses or deploys innovative and scalable methods and technology to accelerate clinical evidence into real-world practice.” Fresenius Kabi received the award on July 24<sup>th</sup> at Premier’s annual Breakthroughs Conference & Exhibition.

(Source: Fresenius Kabi [News Release](#), 8/5/24)

**Macopharma** recently [announced](#) the publication of a [paper](#) in *Stem Cells Translational Medicine* titled “Mitigation of Supply Chain Challenges in Cell Therapy Manufacturing: Perspectives from the Cord Blood Alliance.” According to the company, the article examined, “the root causes and impacts of three significant supply chain issues affecting cord blood banking and the broader cell therapy field. It discusses the shortage of Hespan, the discontinuation of medical device marking for the Sepax system, and new European regulations on plasticizers in cord blood collection bags.” Additionally, the announcement noted, “[t]he authors present systematic mitigation strategies implemented by cord blood stakeholders to address these challenges, emphasizing the importance of unified efforts to negotiate resolutions with providers and regulators.”

(Source: Macopharma [Announcement](#), 7/29/24)

**Citation:** Killela, P., Herrity, K., Frontier, L., *et al.* “[Mitigation of supply chain challenges in cell therapy manufacturing: perspectives from the cord blood alliance.](#)” *Stem Cells Translational Medicine*. 2024. 💧



## CALENDAR

**Note to subscribers:** Submissions for a free listing in this calendar (published weekly) are welcome. Send information to [newsletter@americasblood.org](mailto:newsletter@americasblood.org). (For a more detailed announcement in the weekly “Meetings” section of the newsletter, please include program information.)

### 2024

Sept. 16-18. **2024 U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) Science Symposium (Hybrid), Silver Spring, Md.** [Registration](#) is open. More information available [here](#).

Sept. 17. **America’s Blood Centers (ABC) Webinar: Cybersecurity: Threats & Preventative Actions.** More information and a link to registration are available [here](#).

Sept. 18-19. **2024 ADRP Master Class: Bring in the Coach — The Path to Effective Leadership (Virtual).** More information available [here](#).

Sept. 19. **National Institutes of Health (NIH) Department of Transfusion Medicine NIH Clinical Center and the American Red Cross 43<sup>rd</sup> Annual Immunohematology and Blood Transfusion Symposium (Virtual).** [Registration](#) is open. More information available [here](#).

Sept. 24. **U.S. Department of Health and Human Services (HHS) Sickle Cell Disease Summit (Hybrid), Washington, D.C.** More information available [here](#).

Sept. 24. **FDA Webinar: Labeling Requirements for *In Vitro* Diagnostic Products (IVD), Including Laboratory Developed Tests (LDTs), Under 21 CFR 809.10(b).** More information available [here](#).

Sept 26. **ABC Women’s Executive Leadership Community (WELC) Webinar: “Authentic Confidence.”** More information and a link to registration are [available](#) to ABC members.

Sept. 30-Oct. 3. **American Association of Tissue Banks (AATB) Annual Meeting, Denver, Colo.** [Registration](#) is open. More information available [here](#).

Oct 16. **FDA Advancing Rare Disease Therapies Through an FDA Rare Disease Innovation Hub (Hybrid), Silver Spring, Md.** [Registration](#) is open. More information available [here](#).

Oct. 16-17. **Biomedical Excellence for Safer Transfusion (BEST) Fall Meeting, Galveston, Texas.** More information available [here](#).

Oct. 19-22. **Association for the Advancement of Blood & Biotherapies (AABB) Annual Meeting, Houston, Texas.** More information available [here](#).

Oct. 28. **Centers for Disease Control & Prevention (CDC) Sickle Cell Data Collection (SCDC) Summit 2024 (Virtual).** [Registration](#) is open. More information available [here](#).

Oct. 30. **FDA Patient Engagement Advisory Committee Meeting on Patient-Centered Informed Consent in Clinical Study (Virtual).** More information available [here](#).

Nov. 6-7. **ABC Women’s Executive Leadership Community (WELC) Workshop, San Antonio, Texas.** [Registration](#) is open. More information is available [here](#).

Nov. 6-7. **Centers for Disease Control and Prevention (CDC Clinical Laboratory Improvement Advisory Committee (CLIAC) Meeting (Virtual).** More [information](#) is available [here](#).

Nov. 13. **2024 ADRP International Showcase.** More information coming soon.

(continued on page 9)





## CALENDAR (continued from page 8)

Nov. 19-20. **Trauma Hemostasis & Oxygenation Research (THOR) Network Emergency Transfusion in Females with Childbearing Potential: Mitigating the Risks of Hemolytic Disease of the Fetus and Newborn Meeting.** Bethesda, Md. [Registration](#) is open. More information available [here](#).

Nov. 19-20. **Plasma Protein Forum.** Washington, D.C. More information available [here](#).

## 2025

Mar. 10-12. **ABC Annual Meeting.** Arlington, Va. More information available [here](#).

May 6-8. **2025 ADRP Annual Conference.** Oklahoma City, Okla. More information available [here](#).

May 20-21. **International Plasma Protein Congress.** Warsaw, Poland. More information is coming soon.

Oct. 12-15. **AATB Annual Meeting.** Atlanta, Ga. More information is coming soon.

Oct. 25-28. **AABB Annual Meeting.** San Diego, Calif. More information is coming soon.

Nov. 17-20. **American Society for Clinical Pathology (ASCP) Annual Meeting.** Atlanta, Ga. More information coming soon. 💧

## CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: [newsletter@americasblood.org](mailto:newsletter@americasblood.org)

## POSITIONS

**Marketing Executive.** LifeSouth Community Blood Centers is looking for a highly skilled leader with a solid understanding of marketing principles and techniques, a data-driven approach, and a passion for innovation, to join the team as Marketing Executive in Gainesville, FL. This position is responsible for the overall marketing strategy across the organization. This position requires active communication with executive leadership and department directors within the organization to ensure adequate planning and execution of strategic marketing plans. This position is dedicated to advancing the organization's objectives in blood donation, cord blood services, cellular therapy, new business development, and meeting patient needs. Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit our careers page to learn more about this position, and apply [here](#)!

**Immunohematology Reference Lab Medical Technologist.** LifeSouth Community Blood Centers is looking for an experienced Laboratory Medical Technologist, with a passion for making a difference, to join our Immunohematology Reference Laboratory team in Atlanta, GA. The position is responsible for following established policies and procedures, identifying problems that may adversely affect test performance or reporting of test results, and either correct the problems or immediately

notify a supervisor, manager, or director. The IRL Medical Technologist will resolve immunohematology and compatibility problems to provide the safest donor blood for the patients in our community. We focus on providing the best possible customer service. Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit our careers page to learn more about this position, and [apply here](#)!

**Immunohematology Reference Lab Medical Technologist.** LifeSouth Community Blood Centers is looking for an experienced Laboratory Medical Technologist, with a passion for making a difference, to join our Immunohematology Reference Laboratory team in Jacksonville, FL. The position is responsible for following established policies and procedures, identifying problems that may adversely affect test performance or reporting of test results, and either correct the problems or immediately notify a supervisor, manager, or director. This individual will resolve complex immunohematology and compatibility problems to provide the safest donor blood for the patients in our community. We focus on providing the best possible customer service. Join our team and help us continue our dedication to making sure the blood is there

(continued on page 10)



## POSITIONS (continued from page 9)

when you or your family is in need. Visit our careers page to learn more about this position, and [apply here!](#)

**IRL Supervisor.** Bloodworks Northwest, a recognized leader in transfusion medicine, currently has an opening for an IRL Supervisor in the Immunohematology Reference Laboratory. Key responsibilities include supervising departmental staff, ensuring the management of departmental projects, and participating in interdepartmental projects according to established priorities and timelines. Coordinating quality review and management of errors. Providing technical expertise in IRL testing and the development and implementation of new methods and as needed and perform clinical laboratory testing. Requirements include: Must qualify as General Supervisor, High Complexity Testing, under CLIA personnel requirements found in Subpart M of the Code of Federal Regulations. Certification as a Specialist in Blood Banking (SBB) is required. Certification as a Medical Laboratory Scientist (MLS) is preferred. Five years of laboratory technical experience with at two years of experience in immunohematology reference testing is required or an equivalent combination of education and experience. Three years of laboratory supervisor or Lead experience is preferred. Demonstrated expertise in immunohematology reference testing. Basic knowledge of molecular techniques is preferred. We offer competitive benefits: Medical, dental, vision, life insurance, retirement plan, subsidized back-up childcare program, subsidized transit program, educational reimbursement and more! Interested candidates should apply directly on our website at [www.bloodworksnw.org/careers](http://www.bloodworksnw.org/careers).



**Assistant/Associate Director, Blood Transfusion Service (Massachusetts General Hospital; Boston, Massachusetts).** The Department of Pathology at the Massachusetts General Hospital (MGH), a founding hospital of Mass General Brigham, and a major teaching affiliate of the Harvard Medical School, seeks a full-time, early- or mid-career, academically oriented transfusion medicine physician. The successful candidate will combine clinical and teaching activities with a research program in a field relevant to transfusion medicine, hematology, or hemostasis. The Blood Transfusion Service at MGH encompasses an FDA-licensed donor center, therapeutic apheresis, an outpatient transfusion/infusion clinic, a transfusion service, and progenitor cell collection and processing. We collaborate closely with colleagues in bone marrow and solid organ transplantation, CAR-T cell therapy, cardiac surgery, trauma and critical care, neurology, and pediatrics. Our faculty also work closely with transfusion medicine faculty within the MGB network. Service and teaching responsibilities will

be shared with two full- and several part-time staff physicians. Candidates must be BC/BE in Transfusion Medicine, with primary training in either Pathology or Hematology/Oncology (adult or pediatric). Academic rank as Associate Professor, Assistant Professor or Instructor and salary will be commensurate with experience and accomplishments. Interested candidates should send a personal statement with research interest, three potential referees and Curriculum Vitae to: Dr. Robert Makar; Director, Blood Transfusion Service; Department of Pathology; Massachusetts General Hospital; 55 Fruit Street, GRJ 148; Boston, MA 02114. Email: [rmakar@mgh.harvard.edu](mailto:rmakar@mgh.harvard.edu) C/O Diane Savickas [dsavickas@mgb.org](mailto:dsavickas@mgb.org). We are an equal opportunity employer, and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability status, protected veteran status, gender identity, sexual orientation, pregnancy, and pregnancy-related conditions, or any other characteristic protected by law.



**HARVARD MEDICAL SCHOOL  
TEACHING HOSPITAL**